UPDATED SAFETY DATA FROM A RANDOMIZED PHASE 2 TRIAL OF HEDGEHOG PATHWAY INHIBITOR GDC-0449 VS. PLACEBO WITH FOLFOX OR FOLFIRI AND BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
ANNALS OF ONCOLOGY（2010）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要